NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT06204809,"Safety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants with Myotonic Dystrophy Type 1",https://clinicaltrials.gov/study/NCT06204809,FREEDOM-DM1,RECRUITING,"The primary purpose of the study is to evaluate the safety and tolerability of single intravenous (IV) doses of PGN-EDODM1 administered to participants with Myotonic Dystrophy Type 1 (DM1).

The study consists of 2 periods: A Screening Period (up to 30 days) and a Treatment and Observation Period (16 weeks).",NO,Myotonic Dystrophy 1,DRUG: PGN-EDODM1 for infusion|OTHER: Placebo,"Number of participants with Adverse Events, Serious Adverse Events, with abnormal Clinical Laboratory tests, abnormal ECGs, and abnormal Vital Signs, Baseline to Week 16","Maximum Observed Plasma Drug Concentration (Cmax) of PGN-EDODM1, Baseline up to Day 3|Time to Maximum Observed Plasma Drug Concentration (Tmax) of PGN-EDODM1, Baseline up to Day 3|Apparent Terminal Half-Life (tÂ½) of PGN-EDODM1, Baseline up to Day 3|Area Under the Concentration-time Curve of PGN-EDODM1, Baseline up to Day 3",,PepGen Inc,,ALL,ADULT,PHASE1,32,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",PGN-EDODM1-101,2023-12-12,2025-04,2025-04,2024-01-12,,2024-12-10,"UCI Center for Clinical Research, Irvine, California, 92697, United States|Stanford University, Palo Alto, California, 94304, United States|University of Kansas Medical Center, Fairway, Kansas, 66205, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|University of Rochester Medical Center, Rochester, New York, 14642, United States|Virginia Commonwealth University, Richmond, Virginia, 23298, United States|Ottawa Hospital Research Institute (OHRI), Ottawa, Ontario, Canada|CIUSSS du Saguenay-Lac-Saint-Jean, Chicoutimi, Quebec, Canada|Salford Royal Hospital, Salford, United Kingdom",
